Evidence map›Paper›PMID 41584839›Full record

ArticleFrontiers in cell and developmental biology2025

Developmental and reproductive toxicity assessment of sporoderm-removed

Junxiu Liu, Yisheng Song, Chuanhuai Chen, Jing Liu, Siming Zhang, Fang Liu, Ruiyu Tian, Jinjin Shao, Lili Zhang, Tingli Bian and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Junxiu Liu *Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Yisheng Song *Zhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Chuanhuai ChenZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Jing LiuZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Siming ZhangZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Fang LiuZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Ruiyu TianZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Jinjin ShaoZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Lili ZhangZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Tingli BianZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Ruimin SunZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Li YuZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Shuizhen PanZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Yunxiang ChenZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Yaoxian XuanZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Hanbo WangJinhua Shouxiangu Pharmaceutical Co., Ltd., Jinhua, China.
Zhenhao LiJinhua Shouxiangu Pharmaceutical Co., Ltd., Jinhua, China.
Ying ChenZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
Lijiang ZhangZhejiang Provincial Key Laboratory of Drug Discovery and Safety Evaluation for Inflammatory Chronic Diseases, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: Following ICH S5 (R3) guidelines, we conducted three non-clinical DART studies: embryo-fetal developmental (EFD) toxicity in rats, Results: Our results showed no maternal toxicity, embryotoxicity, or teratogenicity in rats, apart from reversible drug-mixed feces. The offspring showed no adverse effects on growth, neurodevelopment (Morris water maze), or fertility. Rabbit embryos exhibited normal morphology and organ development. The no-observed-adverse-effect level of RGLS was 4.0 g/kg, which was approximately 20 times the intended clinical dose. Discussion: Overall, our study supports the safe use of RGLS in clinical applications for pregnant and lactating women, indicating that it can be added to a healthy diet.

Indexed as

developmental toxicitymedication safetyno-observed-adverse-effect levelreproductive toxicitysporoderm-removed Ganoderma lucidum spores

Identifiers

PMID41584839
PMCPMC12827563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.